skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity

Abstract

Patients with an autonomously functioning throid nodule (ATN) may present with various clinical, biochemical and scintigraphic features. To optimize 1 dose planning and treatment timing in these patients, relationships between dosimetric data and clinical follow-up events must be established. The authors retrospectively reviewed the records of 88 patients who received 1 (intended dose of 80 Gy) for an ATN, of whom 39 had evidence of extranodular activity (ENA) and 76 presented with overt thyrotoxicosis. In all of the patients, dosage calculation was monitored to estimate precisely both beta and gamma absorbed doses received by the ATN and the nodule-free lobe. The mean duration of follow-up was 75 mo (max 180) and always included biochemical thyroid tests. Finally, they compared the dosimetric profiles of four dosage schemes which had been normalized by simulation to ensure that the same absorbed dose threshold value was always delivered to the ATN. About 75% of the patients were cured at 6 mo for a mean 305 MBq administered. The absorbed doses delivered to the nodule-free lobe to the ATN, mainly in the form of beta irradiation. Life-table estimates for hypothyroidism and death were 9.6% and 22% at 75 mo, respectively. Hypothyroidism mainly developed in patientsmore » with nonsuppressed TSH levels but regardless of ENA, which often accounted for multifocal disease. The authors suggest that fixed doses bordering on 370 MBq are advisable in younger individuals and in patients with mild thyrotoxocosis, while 555 MBq-740 MBq can be administered in other patients and that ENA indicates multifocal autonomy in patients with toxic ATN and is a further indication for radioiodine treatment which should be begun as soon as possible to avoid the development of cardiac complications. 27 refs., 5 tabs.« less

Authors:
; ;  [1]
  1. Necker Hospital, Paris (France)
Publication Date:
OSTI Identifier:
255196
Resource Type:
Journal Article
Journal Name:
Journal of Nuclear Medicine
Additional Journal Information:
Journal Volume: 36; Journal Issue: 2; Other Information: PBD: Feb 1995
Country of Publication:
United States
Language:
English
Subject:
56 BIOLOGY AND MEDICINE, APPLIED STUDIES; HYPERTHYROIDISM; RADIOTHERAPY; THYROID; BETA DOSIMETRY; GAMMA DOSIMETRY; IODINE 131

Citation Formats

Clerc, J., Dagousset, F., and Izembart, M. Radiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity. United States: N. p., 1995. Web.
Clerc, J., Dagousset, F., & Izembart, M. Radiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity. United States.
Clerc, J., Dagousset, F., and Izembart, M. Wed . "Radiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity". United States.
@article{osti_255196,
title = {Radiodine therapy of the autonomous thyroid nodule in patients with or without visible extranodular activity},
author = {Clerc, J. and Dagousset, F. and Izembart, M.},
abstractNote = {Patients with an autonomously functioning throid nodule (ATN) may present with various clinical, biochemical and scintigraphic features. To optimize 1 dose planning and treatment timing in these patients, relationships between dosimetric data and clinical follow-up events must be established. The authors retrospectively reviewed the records of 88 patients who received 1 (intended dose of 80 Gy) for an ATN, of whom 39 had evidence of extranodular activity (ENA) and 76 presented with overt thyrotoxicosis. In all of the patients, dosage calculation was monitored to estimate precisely both beta and gamma absorbed doses received by the ATN and the nodule-free lobe. The mean duration of follow-up was 75 mo (max 180) and always included biochemical thyroid tests. Finally, they compared the dosimetric profiles of four dosage schemes which had been normalized by simulation to ensure that the same absorbed dose threshold value was always delivered to the ATN. About 75% of the patients were cured at 6 mo for a mean 305 MBq administered. The absorbed doses delivered to the nodule-free lobe to the ATN, mainly in the form of beta irradiation. Life-table estimates for hypothyroidism and death were 9.6% and 22% at 75 mo, respectively. Hypothyroidism mainly developed in patients with nonsuppressed TSH levels but regardless of ENA, which often accounted for multifocal disease. The authors suggest that fixed doses bordering on 370 MBq are advisable in younger individuals and in patients with mild thyrotoxocosis, while 555 MBq-740 MBq can be administered in other patients and that ENA indicates multifocal autonomy in patients with toxic ATN and is a further indication for radioiodine treatment which should be begun as soon as possible to avoid the development of cardiac complications. 27 refs., 5 tabs.},
doi = {},
journal = {Journal of Nuclear Medicine},
number = 2,
volume = 36,
place = {United States},
year = {1995},
month = {2}
}